As of Jan 20
| -0.10 / -3.23%|
The 1 analysts offering 12-month price forecasts for MabVax Therapeutics Holdings Inc have a median target of 18.00, with a high estimate of 18.00 and a low estimate of 18.00. The median estimate represents a +500.00% increase from the last price of 3.00.
The current consensus among 1 polled investment analysts is to Buy stock in MabVax Therapeutics Holdings Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.